Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.
Anna TjärnlundQuan TangCecilia WickMaryam DastmalchiHerman MannJana Tomasová StudýnkováRadka ChuraNicola J GullickRosaria SalernoJohan RönnelidHelene AlexandersonEva LindroosRohit AggarwalPatrick GordonJiri VencovskyIngrid E LundbergPublished in: Annals of the rheumatic diseases (2017)
In this pilot study, treatment of patients with DM and PM with abatacept resulted in lower disease activity in nearly half of the patients. In patients with repeat muscle biopsies, an increased frequency of Foxp3+ Tregs suggests a positive effect of treatment in muscle tissue.
Keyphrases
- rheumatoid arthritis
- disease activity
- systemic lupus erythematosus
- clinical trial
- chronic kidney disease
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- prognostic factors
- insulin resistance
- metabolic syndrome
- young adults
- ankylosing spondylitis
- immune response
- open label
- polycyclic aromatic hydrocarbons
- juvenile idiopathic arthritis
- phase iii